MedPath

Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion

Phase 2
Not yet recruiting
Conditions
Rectal Cancer
Recurrent
Registration Number
NCT05807984
Lead Sponsor
Xin Cai
Brief Summary

Prospective phase II clinical study aim to explore the clinical outcome of patients with unresectable locally recurrent rectal cancer (LRRC) treated with re-irradiation by carbon ion radiotherapy (CIRT)

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
31
Inclusion Criteria
    1. pathologically confirmed rectal adenocarcinoma (including mucinous adenocarcinoma and signet-ring cell carcinoma) and LRRC confirmed by biopsy or clinical diagnosis,
    1. received a radical operation for their primary tumor and regional lymph nodes,
    1. received chemo-radiation or radiation in pelvic before CIRT,
    1. received re-irradiation by CIRT after their pelvic radiotherapy.
Exclusion Criteria
    1. received more than once prior radiotherapy in the same treatment field,
    1. time to the last radiotherapy was <1 year,
    1. space between the lesion to organ at risk (OARs) (bladder or digestive tract) was too close (<5 mm).

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
local controlLocal control at 3 years after CIRT

local control rate of the lesion treated by CIRT

Secondary Outcome Measures
NameTimeMethod
progression free survival3 years after CIRT or patient died, measured erery 3 months after CIRT

progression free survival rate after CIRT

overall survival3 years after CIRT or patient died, measured erery 3 months after CIRT

survival rate after CIRT

Trial Locations

Locations (1)

Shanghai Proton and Heavy ion center

🇨🇳

Shanghai, Pudong, China

© Copyright 2025. All Rights Reserved by MedPath